Modulation of Pain with Transcranial Direct Current Stimulation and Diffuse Noxious Inhibitory Controls by Reidler, Jay S.
 
Modulation of Pain with Transcranial Direct Current Stimulation and
Diffuse Noxious Inhibitory Controls
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 16, 2015 1:18:15 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407609
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA  2 
Table of Contents 
 
Title Page                      1 
Table of Contents                    2 
Acknowledgments                    5 
Preface                        7 
Glossary of Abbreviations                  9   
Abstract                      11 
Introduction                       
i.  Chronic Pain: Burden of Disease              13 
ii.  Physiologic Pain: Function and Neurophysiology          14 
iii.  Pathologic Pain                  15 
iv.  Peripheral Sensitization in Chronic Pain            16 
v.  Central Sensitization in Chronic Pain             17 
vi.  Challenges in Pharmacologic Treatments for Pain          18 
vii.  Endogenous Pain Modulation: The Role of Descending Noxious       18 
Inhibitory Controls                 
viii.  Brain Stimulation: A Rapidly Growing Field           20 
ix.  Neurophysiology of tDCS                21 
x.  Scientific and Clinical Uses of tDCS             23 
xi.  Exogenous Pain Modulation Using tDCS            23 
xii.  Combining Techniques for Modulating Pain           24 
xiii.  Magnetic Resonance Spectroscopy of Pain            24 
xiv.  Specific Aims of the Present Study              25   3 
Methods                       
i.  Experimental Design                  27 
ii.  Participants                    27 
iii.  Study Sequence                  27 
iv.  Magnetic Resonance Spectroscopy              28 
v.  Transcranial Direct Current Stimulation            29 
vi.  Assessments                    30 
a.  Sensory Assessments                
b.  Assessment of Potential Confounders           
c.  Cognitive Assessments               
d.  Side effects and Blinding Assessments           
vii.  Statistical Analyses                  33 
Results                        
i.  Side effects, Blinding, and Test for Normality          34 
ii.  Changes in Pressure-Pain Threshold              35 
iii.  Changes in Sensory Threshold              36 
iv.  Behavioral and Cognitive Assessment Results          36 
v.  Brain Metabolite Concentrations and Pain Modulation Response      36 
Discussion                       
i.  Increase in Pain Thresholds                38 
ii.  Increase in Sensory Thresholds              40 
iii.  Review of Adverse and Cognitive Effects            42 
iv.  Insights from Magnetic Resonance Spectroscopy          42 
v.  Limitations                    44   4
vi.  Future Directions                  47 
vii.  Summary and Conclusions                51 
References                      52 
Tables                        
  Table 1. Varying Parameters of tDCS            61 
  Table 2. Side effects of tDCS Administration          62 
Figures                       
  Figure 1. Transcranial Magnetic Stimulation           63 
  Figure 2. Transcranial Direct Current Stimulation          64 
  Figure 3. Experimental Design              65 
 F i g u r e   4 .   M o t o r   C o r t e x   S t i m u l a t i o n   a nd DNIC Increase Pain Thresholds    66 
Appendices                       
  Appendix A: tDCS Screening Questionnaire           67 
  Appendix B: Visual Analog Scale for Anxiety          69 
  Appendix C: Trail Making Tests              70 
  Appendix D: tDCS Side Effects Questionnaire          73 
  Appendix E: tDCS Blinding Questionnaire            74 
 
   5 
Acknowledgements 
I feel deeply grateful to the many people who helped shaped my research career over the 
past 5 years.  Since my first year in medical school, Dr. Felipe Fregni has been an outstanding 
mentor. He has taught me so much about research, medicine, and life generally. His commitment 
to discovery and innovation in medicine has been a true inspiration and I look forward to 
carrying forward the many lessons I’ve learned from him throughout my career.  Dr. Fregni 
provided exceptional support and advice as I planned and completed this study, carefully 
reviewed the manuscript, and offered countless helpful suggestions.  
I would like to acknowledge and thank the other lab members and collaborators who 
contributed to this study: Mariana Mendonca randomized the participants in this double-blinded 
experiment and administered the active and sham stimulation. Andrew Ellison and Yansong 
Zhao at Boston University School of Medicine Center for Biomedical Imaging helped with the 
technical aspects of magnetic resonance spectroscopy scanning of subjects. Drs. Robert 
Lenkinski and Xiaoen Wang from the department of Radiology at Beth Israel Deaconess 
Medical Center processed our magnetic resonance spectroscopy data and contributed to the 
related methods section in the manuscript. Drs. Serge Marchand and Andrea Motta from the 
University of Sherbrooke helped review and refine the manuscript. Marcus Santana, Lydia Latif, 
Joao Amadera, Rasheda El-Nazer, Laura Sherman, Lauren Richardson, and Jennifer Schadler 
provided extremely helpful suggestions and administrative support, without which this study 
would not have been possible.  
Thank you to the other members of our lab with whom I’ve developed close friendships 
over the years, including Marcel Simis, Soroush Zaghi, Daniel Pimentel, Joao Amadera, Kayleen 
Weaver, and Sarah Daly.   6 
Special thanks to Drs. D’Amico, Shields, and Fazio and to Csilla Kiss for their 
unwavering support since my first day in medical school. 
Finally, I want to express my deepest gratitude to my parents, grandparents, siblings, 
daughter Layla, and wife Estie, who have been immeasurably devoted to me and made me who I 
am.   
 
Funding 
This work was supported in part by the National Institute of Diabetes and Digestive and 
Kidney Diseases at the National Institutes of Health, grant number R21 7R21DK081773. The 
Office of Enrichment Programs at Harvard Medical School and the Laboratory of 
Neuromodulation provided me with a stipend during the summer following my first year in 
medical school, which was spent full-time working on this project. The investigators do not have 
any conflicts of interest. 
 
 
 
 
     7 
Preface 
I have been involved in Dr. Fregni’s Laboratory of Neuromodulation at Spaulding 
Rehabilitation Hospital since early in my first year in medical school. During my time in the lab, 
I have led and contributed to a number of research projects that have resulted in the following 
works:  
1.  Reidler, J.S., Nascimento, B., Wu, D.S.K., Carvas, M., Massuyama, B.K., de Oliveira, B.M.R., 
Zaghi, S., de Rezende, D.T., El-Nazer, R., Walyson, N.G., Merabet, L., & Fregni, F. (2010). 
Modulation  of  inhibitory  systems  to  enhance  motor  rehabilitation:  insights  for  the  use  of 
noninvasive brain stimulation. Psychology & Neuroscience, 3 (2), 151-60. 
 
2.  Reidler, J.S., Zaghi, S., & Fregni, F. (2011). Neurophysiological Effects of Transcranial Direct 
Current Stimulation. In Neurofeedback and Neuromodulation Techniques and Applications. 
London: Elsevier Inc., eds. Coben and Evans, pp. 319-50. 
 
3.  Reidler, J.S., Mendonca, M.E., Santana, M.B., Wang, X., Lenkinski, R., Motta, A.F., Marchand, 
S., Latif, L., & Fregni, F. (2012). Effects of Motor Cortex Modulation and Descending Inhibitory 
Systems on Pain Thresholds in Healthy Subjects. Journal of Pain, (13)5, 450-8. 
 
4.  Simis, M., Reidler, J.S., Macea, D.D., Duarte, I.M., Wang, X., Lenkinski,  R., Petrozza, J.C. & 
Fregni,  F.  (under  review).  Investigation  of  Central  Nervous  System  Dysfunction  in  Chronic 
Pelvic Pain Using Magnetic Resonance Spectroscopy and Non-Invasive Brain Stimulation. 
 
This thesis focuses on an investigation that I led under Dr. Fregni’s supervision over the 
course of my first three years in medical school, which was published in the Journal of Pain 
(Reidler et al., 2012; #3 above). The introduction and discussion sections of this thesis also draw 
on some of the work from my other publications. I worked on the present investigation full-time 
during the summer between my first and second year in medical school and part-time during the 
semesters leading up to and following that summer.  I was involved in all aspects of the 
experiment including study design, participant recruitment, questionnaire administration, sensory 
testing, magnetic resonance spectroscopy scanning, statistical analyses, manuscript preparation, 
submission for peer review, and critical revision. Many other people contributed to this study and 
I have outlined their contributions in the Acknowledgments section above.    8 
Of note, the present study in healthy subjects was designed in conjunction with another 
investigation, which examines the use of tDCS for treating chronic pelvic pain. While the present 
study independently examines the pain modulatory effects of tDCS and DNIC in healthy 
subjects, we eventually compared our findings in this control group to those observed in patients 
with chronic pelvic pain. The chronic pelvic pain study was recently completed and I am second 
author on the manuscript that has been submitted for publication (Simis et al., under review; #4 
above). I have chosen to present in this thesis only data for which I was the lead investigator and 
therefore did not include the chronic pelvic pain study.  
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Glossary of Abbreviations 
ACC: anterior cingulate cortex 
BDI: Beck depression inventory 
CIPA: congenital insensitivity to pain with anhidrosis 
CNS: central nervous system 
Cr: creatine 
CS: conditioning stimulus 
DC: direct current 
DNIC: diffuse noxious inhibitory controls 
DRG: dorsal root ganglion 
EEG: electroencephalogram 
GABA: gamma-aminobutyric acid 
Gln: glutamine 
Glu: glutamate 
GM-CSF: granulocyte-macrophage colony stimulation factor 
¹H-MRS: proton magnetic resonance spectroscopy 
LTP: long-term potentiation 
M1: primary motor cortex 
MAPK: mitogen-activated protein kinase 
MEP: motor-evoked potential 
mI: myoinositol 
MRI: magnetic resonance imaging 
MRS: magnetic resonance spectroscopy 
NAA: N-acetylaspartate    10 
NAAG: N-acetylaspartateglutamate 
NGF: nerve growth factor 
NIH: National Institutes of Health 
PAG: periaqueductal gray 
PLC: phospholipase C 
PNS: peripheral nervous system 
PPT: pressure-pain threshold 
PRESS: point resolved spectroscopy 
rTMS: repetitive transcranial magnetic stimulation 
RVM: rostroventral medulla 
SRD: subnucleus reticularis dorsalis 
tDCS: transcranial direct current stimulation 
TE: echo time 
TENS: transcutaneous electrical nerve stimulation 
TMS: transcranial magnetic stimulation  
Total NAA: N-acetylaspartate + N-acetylaspartateglutamate 
TR: repetition time 
TRP: transient receptor potential 
TS: testing stimulus 
VAS: visual analog scale 
VFH: Von Frey hair assessment 
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Abstract 
Background: While pain is essential for physiological functioning, chronic or pathologic pain is 
responsible for a major burden of disease in society. Novel approaches to treating acute and 
chronic pain have employed neuromodulatory tools to target the central and peripheral neural 
structures that mediate pain. Transcranial direct current stimulation (tDCS), for example, is a 
safe, non-invasive brain stimulation technique that has been shown in preliminary studies to 
reduce chronic pain when applied to the primary motor cortex. In contrast to this exogenous 
neuromodulatory approach, diffuse noxious inhibitory controls (DNIC) refers to endogenous 
pain regulatory mechanisms that decrease pain following introduction of heterotopic noxious 
stimuli. This thesis explores whether combining these exogenous and endogenous pain 
modulation approaches synergistically increases the threshold at which pain is perceived.  
Methods: We conducted a double-blinded, randomized, placebo-controlled trial with a crossover 
design to investigate the effects of tDCS and DNIC on pain thresholds in 15 healthy human 
subjects. Pain thresholds were assessed prior to and following administration of active tDCS, 
sham tDCS, cold-water-induced DNIC, and combined active tDCS and DNIC. Using magnetic 
resonance spectroscopy, we examined whether baseline concentrations of brain metabolites such 
as N-acetylaspartate in pain-related regions of interest were associated with responses to the 
varying neuromodulatory conditions. 
Results: Pain thresholds significantly increased following both active tDCS and the DNIC 
paradigm. These modulatory approaches appeared to have additive effects when combined. Pain 
threshold increases after active tDCS were positively correlated with baseline levels of N-
acetylaspartate, a marker of good neural function, in the anterior cingulate cortex and negatively 
correlated with baseline levels of glutamine in the thalamus.   12 
Conclusions: Combining endogenous pain regulatory mechanisms with exogenous stimulation 
of the motor cortex can more effectively increase pain thresholds in healthy humans. Future 
studies should examine whether existing pain therapies may be enhanced with noninvasive brain 
stimulation and activation of DNIC. They should also assess whether brain metabolite levels can 
be utilized to predict clinical response to therapeutic interventions.  
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Introduction 
Pain represents a major challenge in clinical medicine. It is associated with a wide array 
of injuries and pathologies, sometimes resulting secondary to discrete causes such as malignancy 
or surgical intervention, and other times constituting the primary pathology, as in neuropathic 
pain and fibromyalgia. This thesis explores the possibility of modulating the experience of pain 
using a non-invasive brain stimulation technique known as transcranial direct current stimulation 
(tDCS) and endogenous pain regulatory mechanisms known as diffuse noxious inhibitory 
controls (DNIC).  In this introduction, I present an up-to-date review of the literature surrounding 
the present field of investigation. This includes discussion of the burden of disease associated 
with chronic pain, the neurobiology of physiologic pain, the peripheral and central sensitization 
processes involved in the development of pathologic pain, and current limitations in developing 
new pharmacologic treatments for pain. I then provide background on the two pain modulation 
approaches examined here, tDCS and DNIC, including their theorized mechanisms of action and 
neurophysiology. Finally, I detail the aims of the present investigation and our related 
hypotheses. 
 
Chronic Pain: Burden of Disease 
Chronic pain, or pain persisting past three months, is associated with a great burden of 
disease in society. It is estimated that 1.5 billion people around the world suffer from various 
forms of chronic pain, including approximately 100 million in the United States alone.
1 This 
amounts to a higher prevalence than the number of individuals affected by cancer, diabetes, and 
heart disease combined.
1,2 Chronic pain is a heterogeneous condition that presents in many 
forms, such as low back pain, chronic migraine, post-traumatic pain, and chronic pelvic pain. In 
2011, the Institute of Medicine estimated that chronic pain generates up to $635 billion annually   14 
in direct health care spending and lost worker productivity in the United States (about $2000 
annually per capita).
1 Thus, chronic pain represents a major public health challenge requiring 
innovative treatment approaches.   
 
Physiologic Pain: Function and Neurophysiology   
In recent years major advances have been made in our understanding of both physiologic 
and pathologic pain. Pain is an evolutionarily conserved phenomenon that plays an important 
protective role in normal functioning.
3 Evidence of this can be drawn from rare cases in which 
genetic mutations lead to a congenital inability to experience pain. For instance, in congenital 
insensitivity to pain with anhidrosis (CIPA), a genetic mutation involved in nerve development 
leads to insensitivity to painful stimuli, while still allowing sensitivity to touch and pressure. 
Individuals with this condition experience recurrent joint dislocations, thermal injuries, 
unrecognized chronic fractures, auto-amputation of fingers and toes, and ulcerations of the lip, 
tongue, oral mucosa, and fingertips due to biting.
4-6 Physiologic pain signals to an organism 
when harm, either external or self-inflicted, may occur, and thus appears essential for survival.  
  Pain is mediated by neural activity that is distributed throughout the peripheral and 
central nervous system (PNS and CNS, respectively). The peripheral neurons involved in pain 
sensation are called nociceptors. These are classified by axon type into A-delta (Aδ) fibers, 
which are thinly myelinated and fast-conducting, and C fibers, which are unmyelinated and 
slow-conducting.
3,7 This is in contrast to A-beta (Aβ) fibers and proprioceptors, which are 
responsible for non-nociceptive sensory functions such as light touch, movement, and vibration. 
Nociceptor nerve endings contain a diverse array of ion channels that are responsible for 
transducing specific noxious stimuli. For instance, hot temperatures are transduced by transient 
receptor potential (TRP) channels such as TRPV1 and TRPV2, while cold temperatures are   15 
transduced by TRPM8 and Nav1.8.
8-10 Acid-sensing channels known as ASICs respond to high 
concentration of protons, while Piezo1 and Piezo2 transduce mechanical pain.
8,11 When 
activated, these ion channels stimulate a transient potential that is amplified by sodium channels 
Nav1.7, Nav1.8, and Nav1.9 in the terminal nerve.
12,13 When the nerve reaches threshold, an 
action potential is triggered that transmits the nociceptive information from the peripheral 
nervous system into the central nervous system. Interestingly, loss-of-function mutations in the 
Nav1.7 gene (SCN9A) have been reported to cause pain insensitivity, while gain-of-function 
mutations in the gene can cause an extreme pain disorder.
14,15 
  Action potentials travel through the afferent, nociceptor axon and reach the soma (cell 
body), which is found in the dorsal root ganglion (DRG). The soma has central terminals 
synapsing in the superficial laminae (I and II) of the spinal dorsal horn.  Circuits within the 
spinal cord process sensory input and relay them to brain centers via multiple neural tracts. The 
lateral spinothalamic tract projects to the lateral thalamus where the discriminative and sensory 
components of pain are processed. The medial aspect of the spinothalamic tract and the 
spinoparabrachial tract project to the medial thalamus and limbic structures, such as the anterior 
cingulate cortex (ACC) and central nucleus of the amygdala, which are thought to mediate the 
emotional and aversive aspects of pain.
7 Ultimately, pain is perceived in the cerebral cortex and a 
response is generated, such as a cortico-spinal signal to activate withdrawal from the noxious 
stimulus.
7,16 Of note, reflexive withdrawal mechanisms triggered at the level of the spinal cord 
sometimes take place as well.
16  
 
Pathologic Pain 
While pain is essential for physiologic functioning, it can become maladaptive in 
pathological conditions such as inflammation, cancer, neuropathy, viral infections, and diabetes.
7   16 
Chronic pain can persist long after an acute injury has taken place or arise without any clear 
pathological trigger.  Patients often complain of spontaneous, ongoing pain that may be different 
in mechanism from the stimuli that evoked the initial pain.
7 They also commonly experience 
hyperalgesia and allodynia in the chronic pain region. Hyperalgesia constitutes increased 
sensitivity to painful stimuli (i.e., noxious stimuli produce greater pain than usual).  Allodynia 
refers to painful sensations in response to stimuli that are typically not painful. Recent evidence 
suggests that these chronic changes reflect endogenous sensitization over time of the peripheral 
and central neural structures that mediate pain.
7 
 
Peripheral Sensitization in Chronic Pain 
Peripheral sensitization appears to play a role in many chronic pain conditions. This 
manifests as a reduction in the threshold of nociceptor reactivity or as an increase in magnitude 
of reactivity.
3 These changes are induced by molecules released at the site of inflammation by 
nociceptors and non-neuronal cells, such as mast cells, macrophages, and neutrophils.  These 
chemical mediators influence nociceptor excitability at the transcriptional or post-translational 
level and include prostaglandins, protons, ATP, leukotrienes, and growth factors. For instance, 
nerve growth factor (NGF) and granulocyte-macrophage colony stimulation factors (GM-CSF) 
recruit downstream enzymes such as phospholipase C (PLC) and mitogen-activated protein 
kinase (MAPK), which activate transducer molecules such as Nav1.8 and TRPV1, increase 
protein transcription rates, and ultimately raise nociceptor excitability.
8,17,18 Peripheral 
sensitization in chronic pain is also mediated by sensitization in the dorsal root ganglia.  For 
instance, in chronic neuropathic pain, neutrophils and T cells have been shown to invade DRG 
somata of nociceptors, which become a source of ectopic pain discharges.
19  
   17 
Central Sensitization in Chronic Pain 
In addition to peripheral sensitization, chronic pain involves sensitization of pain-related 
structures within the central nervous system.
3 The synaptic communication between primary 
afferent neurons and secondary afferent (spinal) neurons is largely mediated by glutamate. Thus 
glutamatergic receptors, which are modulated by neuropeptides such as substance P, play a 
significant role in determining the strength of synaptic transmission and ultimately the strength 
of pain sensation.  In chronic pain, both pre-synaptic and post-synaptic mechanisms lead to long-
term potentiation (LTP) of synapses in the spinal dorsal horn, increasing excitability of spinal 
neurons and therefore raising pain sensitivity at the CNS level.
20,21 For instance, the persistent 
nociceptive activity leading up to chronic pain causes insertion of more glutamate receptors in 
postsynaptic membranes and production of cyclooxygenases and prostaglandins that facilitate 
greater synaptic neurotransmitter release.
7 This activity also drives expression throughout the 
nervous system of genes responsible for producing pain-related proteins such as TRPV1, COX-2, 
and calcium channels.
22,23  
Beyond these molecular changes, structural and connectivity-related changes also take 
place in the CNS during chronic pain states. Studies have demonstrated decreases in gray matter 
volume of the anterior cingulate cortex and dorsolateral prefrontal cortex, altered brain network 
connectivity in circuits involving cognition and autonomic responses, and changes in nerve fiber 
tracts.
7,24-26 These widespread changes lead to altered moods and behaviors, including 
spontaneous pain at rest, anxiety and depression, decreased attention and worsened emotional 
state.
2 Thus, chronic pain involves sensitization and other changes not only in the peripheral 
nervous system, but in the central nervous system as well. 
    18 
Challenges in Pharmacologic Treatments for Pain 
Most pain medications used today, such as acetaminophen, opioids, salicylic acid, 
gabapentin, and non-steroidal anti-inflammatory drugs, target specific mechanisms in pain 
generation that been known for years. These drugs often have limited ability to alleviate pain, 
particularly chronic pain, and the most effective forms can cause substantial side effects such as 
nausea, constipation, cardiovascular complications, respiratory depression, and addiction.
3 
Despite great advances in our understanding of the neurophysiology underlying acute and 
chronic pain, there remain major limitations in our development of new pharmacologic 
treatments. One challenge is that many molecular mediators involved in pain processing at the 
central and peripheral levels, such as PLC and MAPK, are involved in numerous physiologic 
processes and can therefore not be targeted. Another challenge involves the multiple redundant 
mechanisms in pain pathways which prevent us from treating pain with a single drug target.
3  
These limitations have led researchers to examine endogenous mechanisms by which 
pain is inhibited and develop new exogenous tools for treating pain through modulation of 
central nervous system activity. 
 
Endogenous Pain Modulation: The Role of Descending Noxious Inhibitory Controls 
Recent literature suggests that neural transmission of pain signals from the periphery is 
influenced by an endogenous pain regulatory system.
7,27,28 This pain modulatory system spans 
the nervous system, involving cortical (e.g., prefrontal cortex, cingulate cortex, and insular 
cortex), midbrain, and brainstem regions (e.g., periaqueductal gray (PAG), rostroventral medulla 
(RVM), and subnucleus reticularis dorsalis (SRD) of the medulla).
7,29 Descending output from 
these regions project down the spinal cord and can inhibit or facilitate sensory processing in the 
spinal dorsal horn.
7,29   19 
Diffuse noxious inhibitory controls (DNIC) refers to a spinal-medullary-spinal pathway 
within the endogenous pain regulatory system that decreases sensitivity to subsequent pain after 
exposure to an initial noxious stimulus, often summarized as “pain inhibits pain.”
27,30 Recently 
termed “conditioned pain modulation,”
31 DNIC can be examined in laboratory settings by 
administering a noxious stimulus (the “test-stimulus”) after introducing a heterotopic 
conditioning stimulus (the “conditioning-stimulus”).
27 When pain signals ascend through the 
spinal cord from the periphery, supraspinal structures responsible for DNIC (such as the SRD of 
the caudal medulla) respond by triggering descending inhibition of lamina I neurons in the spinal 
dorsal horn.
27,32-34 This inhibition increases the threshold at which pain stimuli are transmitted 
and ultimately perceived. Brainstem regions involved in DNIC such as the SRD are influenced 
by cortical regions such as the prefrontal cortex, explaining why psychological factors seem to 
influence DNIC responses.
34  
Endogenous pain regulatory pathways such as DNIC serve several adaptive roles. For 
instance, they allow an organism to suppress pain during dire circumstances to help achieve 
survival.
7 They also play an important role in inhibiting the processes that lead to central 
sensitization found in chronic pain.
7 Indeed, patients with hypersensitivity to pain and chronic 
pain have been observed to possess impaired DNIC responses.
27,35-39 Interestingly, impaired 
DNIC response on pre-operative testing has been associated with a greater risk of chronic post-
thoracotomy pain.
40 Endogenous pain modulation may also provide a mechanistic basis for 
placebo-induced analgesia.
41 Finally, some have theorized that non-pharmacologic pain therapies 
such as acupuncture and transcutaneous electrical nerve stimulation may contribute to analgesia, 
in part, through activation of DNIC.
7,42-44 
Thus DNIC is a pain regulatory mechanism that endogenously influences the perception 
of pain. It is found to be dysfunctional in chronic pain states and may be involved in non-  20 
pharmacologic pain therapies. In the next section, we will turn to a potential tool for exogenously 
modulating pain known as transcranial direct current stimulation.  First, I will introduce the field 
of non-invasive brain stimulation generally, then discuss the neurophysiology of tDCS in 
particular, and finally discuss the potential use of tDCS in modulating pain. 
 
Brain Stimulation: A Rapidly Growing Field 
  Brain stimulation techniques and applications have been rapidly increasing in 
neuroscience and clinical medicine. The most invasive of these techniques, deep brain 
stimulation, is a method that permits direct and precise stimulation of deep structures in the brain 
such as thalamic, subthalamic, and pallidal nuclei.  This technique has been used to treat 
dystonias in Parkinson’s disease
45 and holds potential for helping those with obsessive 
compulsive disorder
46 and mood disorders.
47 At the cortical level, electrodes placed directly on 
the dura to stimulate the motor cortex have been shown to alleviate chronic neuropathic pain.
48 
These methods of stimulation are limited, however, by the need to surgically penetrate the skull, 
a costly endeavor with significant medical risks. 
  In part due to the above limitations, non-invasive transcranial stimulation techniques have 
been developed which allow for modulation of brain activity at a lower cost and with 
considerably less risk. Perhaps the most well known of these techniques is transcranial magnetic 
stimulation (TMS), which was developed in 1985 and applies a short-lasting magnetic field to 
stimulate electrical currents and action potentials in the underlying cortex (See Figure 1).
49-51 
Among the many brain stimulation techniques available, tDCS is one of the simplest in 
design, involving administration of weak direct current straight through the scalp.
51,52 In its most 
common form, two sponge-based electrodes are attached to a battery-powered current generator 
that delivers weak current (usually below 10 mA). The electrodes are soaked in saline and held   21 
on two separate parts of the scalp with a rubber band that is placed around the head (See Figure 
2). Current traveling through the circuit enters the scalp and scull, reaching the underlying cortex 
and inducing neurophysiological effects.  In contrast to TMS, which triggers action potentials, 
tDCS solely modulates neuronal excitability at subthreshold levels and therefore does not 
directly induce action potentials.  Of note, electroconvulsive therapy is similar to tDCS in design 
but utilizes substantially greater current intensities (>500 mA vs. less than 10mA for tDCS).
53  
Importantly, TMS has provided an important window into the neurophysiology 
underlying the effects of tDCS. TMS can be used to induce motor-evoked potentials (MEPs), for 
instance, by application of TMS to the motor cortex. Since MEP amplitude is correlated with 
motor cortex excitability, TMS can therefore be used to examine the effects of transcranial direct 
current stimulation on motor cortex excitability.
50,54  
 
Neurophysiology of tDCS 
At the turn of the millennium, Nitsche and Paulus demonstrated that tDCS can be used to 
modulate cortical excitability.
55 Using TMS-induced MEPs as a marker of motor cortex 
excitability, they found that application of weak direct current to the scalp was associated with 
changes in cortical excitability up to 40% that lasted several minutes to hours beyond the end of 
stimulation.
55 Importantly, they showed that electrode montage was essential in determining 
tDCS effects. Later studies revealed that while about half of tDCS current diffuses across the 
scalp, sufficient current penetrates the scalp and skull to influence transmembrane neuronal 
potentials and modulate neuronal excitability in the cortex without eliciting action potentials.
56-58 
The immediate effects of tDCS are due to modulation of neuronal membrane potentials at 
subthreshold levels, which increases or decreases the rate of action potential firing. On a cellular 
level, the voltage gradient between electrodes establishes opposing polarities at either end of the   22 
neurons in the electric field. This generates a difference in the transmembrane potential of 
neuronal membranes and thereby causes current to flow across the membrane and through the 
neuron in accordance with resistance properties of the membrane and intracellular space 
59. This 
flow of current modulates the neuronal membrane potential and results in altered spontaneous 
neuronal activity. Usually, anodal stimulation will depolarize membranes to subthreshold levels 
and increase cortical excitability, while cathodal stimulation will hyperpolarize membranes and 
decrease cortical excitability.
60-62 Ultimately, the direction of polarization and changes in 
excitability will depend on the orientation of axons and dendrites in the induced electric field. 
Radman and colleagues, for instance, demonstrated that the neural somata in cortical layers V 
and VI are most susceptible to tDCS effects.
63 
Changes in cortical excitability are dependent on a number of parameters such as 
stimulation duration and current density, with greater durations and larger current densities 
having greater and longer-lasting effects.
55,64-68 (See Table 1 for summary of tDCS parameters 
and related effects). Electrophysiologic and TMS studies have shown that tDCS can modulate 
excitability of cortical areas immediately beneath the electrodes as well as distant areas 
connected to the initial area of stimulation in a polarity-dependent fashion.
69,70 Similarly, fMRI 
and EEG studies reveal that although tDCS has its strongest effects on the underlying cortex, the 
stimulation can provoke widespread and sustained changes in other brain regions as well.
69,71,72  
More recently, tDCS has been observed to influence spinal cord excitability.
73,74 Therefore, 
clinical effects of tDCS on conditions such as chronic pain might be mediated by influences on 
many regions in the central nervous system.  
Neuropharmacological studies suggest that the long-term effects of tDCS, which can last 
well beyond stimulation, likely involve NMDA-receptor dependent mechanisms.
75 Furthermore,   23 
functional near-infrared spectroscopy has shown that tDCS can lead to increased cerebral blood 
flow to the stimulated region.
76 
 
Scientific and Clinical Uses of tDCS 
In recent years, tDCS has been tested for a wide array of scientific and clinical purposes. 
For instance, researchers have utilized it to examine the effects of cortical modulation on 
language,
77 decision-making,
78 emotional pain,
79 sensory perception,
80 and memory.
81 Clinically, 
tDCS has been proposed as a new tool for enhancing motor and memory rehabilitation following 
stroke.
82-85 It is also being tested for modulating mood and cognitive processes such as craving in 
substance abuse.
86-88  
 
Exogenous Pain Modulation Using tDCS 
Primary motor cortex stimulation using tDCS may also be an effective tool for alleviating 
chronic pain. This approach finds theoretical support in the neurosurgical literature, where an 
abundance of evidence suggests that invasive primary motor cortex stimulation can significantly 
reduce chronic pain, with a weighted responder rate of over 70%.
48 While the precise mechanism 
of analgesia is unclear, growing evidence suggests that motor cortex stimulation triggers rapid 
phasic activation in the lateral thalamus, which results in modulation of activity in other pain-
related regions such as the medial thalamus, ventrolateral thalamus, insula, anterior cingulate 
gyrus, and upper brainstem (e.g., periaqueductal gray matter).
89-91 More specifically, lateral 
thalamic modulation leads to inhibition of thalamic sensory neurons, cingulate modulation leads 
to decreased emotional appraisal of pain, and periaqueductal gray modulation leads to 
descending inhibition toward the spinal cord (similar to DNIC).
91,92 Evidence suggests motor 
cortex stimulation may also cause endogenous opioid release and directly inhibit the   24 
somatosensory cortex.
91,93 The motor cortex thus appears to be an “entry port” for modulating 
deep brain structures, with downstream modulatory affects on pain regions in the brainstem, 
limbic system, and spinal cord.
48 
Given the positive results with invasive motor cortex stimulation, researchers have 
examined whether non-invasive stimulation methods such as tDCS may work as well. Indeed, 
tDCS studies have shown positive results in reducing chronic pain in patients with traumatic 
spinal cord injury,
94 terminal cancer,
95 fibromyalgia,
96-98 chronic migraine,
99 refractory oral 
pain,
100 and chronic pelvic pain.
101 A 2010 Cochrane review and more recent 2012 independent 
review reported that motor cortex stimulation with tDCS does have short-term effects on chronic 
pain, but remarked that the data is insufficient to draw firm conclusions.
102,103 
 
Combining Techniques for Modulating Pain 
Growing literature reveals that tDCS as a modulatory technique may be more effective 
when administered in conjunction with other therapeutic modalities. For instance, tDCS coupled 
with visual illusion therapy and transcutaneous electrical nerve stimulation (TENS) has been 
found to be more efficacious in treating chronic pain.
104,105 Likewise, in the setting of motor 
rehabilitation following stroke, outcomes are enhanced when tDCS is combined with constraint-
induced movement therapy.
106 These observations suggest that combination of tDCS with 
activation of endogenous DNIC inhibitory pathways may yield similarly enhanced effects on 
pain modulation.  
 
Magnetic Resonance Spectroscopy of Pain 
  Proton magnetic resonance spectroscopy (¹H-MRS) is a non-invasive magnetic resonance 
imaging technique that can measure concentrations of metabolites, such as N-acetylaspartate   25 
(NAA), in the human brain. MRS has long been utilized to study neurochemical changes in 
patients with neurological and psychiatric disorders, including intracranial neoplasm, stroke, 
depression, and schizophrenia.
107 Abnormalities in metabolite levels have been linked to 
pathological changes in neural tissue. For instance, NAA concentration has been viewed as a 
marker of neural density, viability, and overall function, and decreases may suggest impaired 
neural function.
108-110 In recent years, researchers have used MRS to examine metabolite changes 
in patients with chronic pain.
111 Interestingly, studies have found decreased levels of NAA in the 
thalamus in patients with chronic neuropathic pain,
112 trigeminal neuralgia,
113 and migraine.
114  
Glutamate is an excitatory neurotransmitter known to be involved in pain, and pain relief in 
chronic pain patients has been associated with decreasing glutamate-glutamine levels in the 
insular cortex (glutamine is a precursor to glutamate).
115 In contrast, gamma-aminobutyric acid 
(GABA) is a key inhibitory neurotransmitter involved in pain, and chronic pain patients have 
been shown to have low GABA levels in the insular cortex and to be more sensitive to 
experimental pain.
116 These observations suggest that MRS might be useful as a diagnostic tool 
in chronic pain or as a predictor of response to various therapeutic interventions.  
 
Specific Aims of the Present Study 
  The following aims and hypotheses were set forth for the present study: 
Aim 1: Our primary aim was to compare exogenous (tDCS) and endogenous (DNIC) pain 
modulation approaches and determine whether combining them synergistically increases 
the threshold at which pain is perceived in healthy subjects. The primary outcome was 
change in pain perception threshold, which was measured in pounds of pressure required to elicit 
a pain response.  We hypothesized that these two modulation techniques would significantly 
increase pain thresholds when administered independently and that they would have significant   26 
additive or synergistic effects when combined. Please Note: The terms “pain threshold” and 
“pressure-pain threshold (PPT)” will be used throughout to refer to pain perception threshold 
(i.e., the threshold at which subjects begin to perceive pain caused by mechanical pressure). 
Pain tolerance threshold (i.e., the threshold at which subjects can no longer tolerate pain) is an 
outcome that was not examined in this study for ethical and subject recruitment reasons. 
 
Aim 2: Our secondary aim was to determine whether active tDCS alters the threshold for 
sensory perception as compared with sham tDCS. This outcome (“sensory threshold”) was 
measured as the smallest von Frey monofilament thickness necessary for perceiving sensation. 
This aim was exploratory in nature and we did not power our study for this aim.   
 
Aim 3: Our final aim was to determine whether baseline neurochemical concentrations in 
the motor cortex, thalamus, and anterior cingulate cortex significantly correlate with 
subject responses to the pain modulatory interventions. We predicted that lower baseline 
glutamate and glutamine levels in our regions of interest would be associated with greater pain 
threshold increases following stimulation (and that this association would not be observed in the 
occipital cortex, which was our control region). This hypothesis follows from a recent study that 
found decreased baseline levels of glutamate-glutamine to be positively correlated with chronic 
pain improvement following non-invasive brain stimulation.
117 This aim was exploratory in 
nature and we did not power our study for this aim. 
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Methods 
Experimental Design 
We performed a double-blinded, randomized, placebo-controlled trial with a crossover 
design to investigate the effects of tDCS and DNIC on pain thresholds in healthy human 
subjects. The protocol for the investigation was approved by Spaulding Rehabilitation Hospital’s 
institutional review board. Prior to participation, the subjects provided written, informed consent.    
 
Participants 
We recruited subjects between the ages 18 and 64 (inclusive) from the greater Boston 
area using online listings and flyers. Criteria for exclusion included the following: chronic pain 
symptoms in the past six months, history of psychiatric or neurological disorders, substance 
abuse history in the past six months, routine use of prescription drugs, pregnancy, and presence 
of tDCS or MRI contraindications (e.g., implanted brain medical devices; see Appendix A). We 
chose conservative estimates in our sample size calculations. Assuming alpha of 5% and beta of 
20% (power = 80%), if we were to use 15 subjects in this crossover experiment, we calculated 
that we could detect differences between groups of 0.45 using two-tailed t-tests. This is a smaller 
effect size than in a previous study performed in our lab
118 and was therefore deemed sufficient 
for examining our hypothesis. This study included 15 participants (mean age 36.7±11.0 years, 9 
females). The subjects and rater were all blinded to the stimulation conditions (active vs. sham 
tDCS). 
 
Study Sequence 
The study took place over the course of three visits. During Visit 1, participants 
underwent magnetic resonance spectroscopy to assess baseline concentrations of metabolites in   28 
specific brain regions.  Within three days of Visit 1, subjects were randomized by blocks of four 
subjects to receive either active or sham tDCS (Visit 2). During this session, tDCS administration 
was preceded and followed by sensory and cognitive assessments. Seven or more days after Visit 
2, subjects experienced identical procedures as in Visit 2, with the only difference being that 
conditions of stimulation were interchanged (sham or active tDCS, respectively). A diagram of 
the experimental design is presented in Figure 3. 
 
Magnetic Resonance Spectroscopy 
We scanned each subject using MRS to assess the baseline levels of glutamate and other 
neural metabolites in brain regions of interest related to pain. ¹H-MRS was performed with a 
Philips Achieva 3.0T (Philips Healthcare, Best, Netherlands) that ran Release 2.6 software. 
Subjects were asked to remain still for the entirety of data collection, which lasted about 30 
minutes. We acquired single-voxel proton MR spectra and employed LCModel (Stephen 
Provencher Inc., Oakville, Ontario, Canada) to assess ratios of metabolite concentration. We 
positioned the MRS voxels (2 × 2 × 2 cm, 8 cm
3) on the sagittal, axial, and coronal images, 
targeting as regions of interest the thalamus, motor cortex, and anterior cingulate cortex 
(Brodmann area 24).
119,120 Data was also collected from the occipital cortex, which served as the 
control region. We acquired spectra using a point-resolved spectroscopy (PRESS) sequence with 
a spectral width of 5000 Hz, short echo time (TE) of 35 milliseconds, repetition time (TR) of 2 
seconds, 2048 time points, and partial water suppression. Manufacturer-supplied shimming 
procedures were performed.  
We analyzed metabolite concentrations using LCModel (Stephen Provencher Inc., 
Oakville, Ontario, Canada). We determined levels of glutamate (Glu), glutamine (Gln), N-
acetylaspartate (NAA), N-acetylaspartateglutamate (NAAG), NAA+NAAG (total NAA),   29 
creatine (Cr), myoinositol (mI), and choline by fitting a linear combination of a basis set of 
metabolite model spectra to the data. We analyzed the spectrum set from 0.2ppm up to 3.8ppm 
with no water scaling or eddy-current correction. The metabolite concentrations were reported in 
terms of mM and ratios relative to the Cr peak. For each subject, the metabolite concentrations 
and metabolite-to-creatine ratios were determined in the acquired spectra.  
 
Transcranial Direct Current Stimulation 
We administered direct current (DC) to the scalp using rubber electrodes enclosed in 
saline-soaked sponges (35 cm
2). Rubber bands were used to hold the electrodes in place on the 
scalp and the electrodes were connected by wires to a battery powered DC generator (Activa 
Dose, Salt lake City, UT). The anode electrode was positioned on the scalp just above the left 
primary motor cortex (M1) and the cathode was placed on the right forehead above the right 
supra-orbital area. This montage seems to be optimal for achievement of pain modulation.
97 We 
localized M1 using the electroencephalogram (EEG) 10/20 system used in previous studies
94 and 
confirmed correct localization through magnetic resonance imaging (MRI) during the MRS scan 
(Visit 1) by placing a Vitamin E on the scalp above the expected M1 location. The electrode 
sponges covered a large portion of the motor cortex, including the segments that mediate activity 
in the upper limb and parts of the lower limb and face, as in Fregni et al. (2006).
94 This 
placement has been shown to increase excitability in M1.
55  
During active stimulation conditions, we administered 2 mA of anodal tDCS to M1 for 
20 minutes in accordance with current stimulation protocols.
121 At the beginning and end of 
stimulation, current level was gradually increased and decreased over the course of 10 seconds in 
order to avoid visual sensations and other side effects. During sham stimulation conditions, 
identical protocols were used, but tDCS current was only administered for the first 30 seconds of   30 
the 20-minute session. Previous literature has demonstrated that application of current for 30 
seconds is a valid method of blinding and that application of current for under 3 minutes does not 
influence cortical excitability.
55,122,123 Subjects receiving active and sham stimulation typically 
feel an itching sensation on the scalp beneath each electrode at the start of stimulation that wanes 
over time. Of note, studies have shown that a single session of active tDCS using 2 mA current is 
safe in non-pregnant, healthy adults, with only minor and short-lasting adverse effects.
68,124  
 
Assessments 
During Visits 2 and 3, a rater (J.S.R.) who was blinded to stimulation conditions 
performed all assessments. These assessments took place immediately before and after the 20-
minute active or sham tDCS sessions and were administered in the following order (explanations 
below):  
(1) Visual Analog Scale for Anxiety  
(2) Beck Depression Inventory (only administered before stimulation)  
(3) Von Frey Hair Assessment  
(4) Pressure-Pain Threshold Assessment  
(5) Pressure-Pain Threshold Assessment During Cold-Water Immersion (DNIC)  
(6) Trail-Making Tests A & B  
(7) Stroop Test  
(8) Simple Reaction Time Test   
Following stimulation, we immediately administered two questionnaires to assess the occurrence 
of adverse effects and determine the success of our blinding procedures. We then repeated all of 
the assessments listed above (excluding the Beck depression inventory).  
   31 
Sensory Assessments 
  As discussed above, our primary aim was to evaluate the influences of tDCS and DNIC on 
the threshold for perceiving pain.  We secondarily aimed to determine whether these modulatory 
approaches affect the threshold for perceiving sensation.  
Von Frey hair (VFH) assessment. We measured subjects’ thresholds for perceiving 
sensation of mechanical pressure using von Frey hair monofilaments with increasing intensities 
(sizes 1.65 to 6.65, which corresponds to target forces of 0.008 grams to 300 grams).
125 While 
the subject’s eyes were closed or averted, we applied increasingly thick monofilaments to the 
thenar region of the subject’s right hand until the subject reported sensing the tactile stimulus. 
The monofilament thickness required to elicit this response was recorded as the sensory 
threshold.  
  Pressure-Pain Threshold (PPT). Pain thresholds (i.e., the threshold at which subjects 
perceive pain) were assessed by applying an increasing amount of blunt pressure using the 1-cm
2 
hard-rubber end of an FDA-approved pain threshold assessment device (Commander Algometer, 
JTECH Medical, Salt Lake City, UT). Higher pain thresholds signify lower sensitivity to painful 
stimuli. Pressure was increasingly applied to the thenar region of the right hand at a rate of 2 
pounds per second until the subjects reported a sensation of pain, at which point the device was 
promptly removed. The pounds of pressure required to elicit a sensation of pain was recorded as 
the pressure-pain threshold, or PPT. This assessment was repeated 3 times.  
  Pressure-Pain Threshold during Cold-Water Immersion. We assessed the degree to which 
pain perception is modulated by DNIC by measuring PPT during immersion of the contralateral 
hand in cold water. In this paradigm, the cold-water immersion was the conditioning-stimulus 
(CS) and the blunt algometric pressure was the testing-stimulus (TS). Subject placed their left 
hands into cold water (10-12˚C) for a total of one minute. During the final 30 seconds of cold-  32 
water immersion, the PPT assessment was performed on the right hand. In a few cases, the 
subjects found 12˚C too cold and the water temperature was therefore increased to more 
tolerable, but still reportedly painfully cold, levels. The water temperature was kept constant for 
each subject across the experiment.  
 
Assessment of Potential Confounders 
  Levels of anxiety and depression were assessed because these variables can be significant 
confounders for variations in pain perception. 
  Visual Analog Scale (VAS) for Anxiety. Subjects rated their current level of anxiety on a 
visual scale from 0 to 10 (see Appendix B).  
  Beck Depression Inventory (BDI). Subjects completed 21 multiple-choice questions to 
determine the presence and extent of depression symptoms.  
 
Cognitive Assessments 
  To monitor for potential adverse effects of tDCS on cognitive function, we administered 
the following cognitive assessments: Trail-Making Tests A & B (assesses attention and working 
memory function; see Appendix C), Stroop Test (assesses selective attention and interference 
proclivity as well as executive function), and Simple Reaction Time Test (assesses attention and 
reaction time using software conducted with Superlab pro v2.0 software (Cedrus Corporation, 
San Pedro, CA)). During 30 trials, subjects were asked to push a response key as soon as they 
saw a 4-cm circle appear on the computer screen. This occurred randomly at 2 to 5 second 
intervals. Response times were recorded and no feedback was provided to subjects). 
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Side effects and Blinding Assessments 
Safety Assessment. Immediately following tDCS administration, subjects completed a 
questionnaire (Appendix D) inquiring about the occurrence of any side effects such as headache, 
scalp pain, tingling, neck pain, scalp burns, skin redness, trouble concentrating, sleepiness, and 
acute mood change.   
Blinding Assessment. Subjects were asked to guess whether they had received active or 
sham tDCS during the session and provide a rating of their level of confidence that they are 
correct (Appendix E).  
 
Statistical analysis   
We analyzed data using Stata
® statistical software (version 9.1, College Station, Texas). 
We conducted a Shapiro-Wilk test for normality. We then ran a repeated-measures analysis of 
variance (ANOVA) in which the dependent variable was change in pain threshold (as measured 
in pounds of algometric pressure). The independent variables included in the ANOVA were 
condition (active tDCS, sham tDCS, DNIC, combined active tDCS and DNIC) and the random 
variable subject ID to control for within subject variability. We performed post-hoc comparisons 
using two-tailed, paired t-tests and corrected for multiple comparisons when appropriate. We 
also used two-tailed paired t-tests to evaluate the effects of active and sham tDCS on sensory 
perception (VFH), level of anxiety (VAS), and cognitive performance (Trail-Making A & B, 
Stroop test, and Simple Reaction Time). Finally, Pearson correlation coefficients were computed 
to determine the relationships between baseline brain metabolite concentrations and changes in 
pain threshold across the varying experimental conditions. We considered these secondary, 
correlational analyses exploratory and therefore did not make Bonferroni corrections (we set 
significance level to p = 0.05).    34 
Results 
Side effects, Blinding, and Test for Normality 
Fifteen participants (mean age 36.7±11.0 years, 9 females) were included in our analysis. 
The study procedures were tolerated well by subjects and no significant adverse effects were 
reported. There were no significant differences in adverse effects reported by subjects when 
comparing active and sham tDCS sessions. Table 2 summarizes the frequency of side effects 
reported following active and sham tDCS. The data was analyzed for potential order effects by 
comparing side effects in those who received active tDCS during the first stimulation session and 
those who received sham tDCS during that session. While there appeared to be order effects for 
various side effects, these order effects were not associated with stimulation condition. For 
example, subjects reported greater occurrence of tingling in the first session regardless of the 
stimulation condition (subjects receiving active-followed-by-sham tDCS reported frequencies of 
83% vs. 50%, respectively, while subjects receiving sham-followed-by-active tDCS reported 
frequencies of 78% and 67%, respectively). For other adverse effects such as sleepiness there did 
not appear to be an order effect (the same analysis showed 33% vs. 33% and 44% vs. 33%, 
respectively). On the blinding assessments, 5 subjects (33%) correctly guessed whether they 
received active or sham tDCS during both sessions and the other 10 subjects did not. This 
guessing success was at the level of chance (p=0.2, comparison between correct and incorrect 
guesses), suggesting that our protocol for sham stimulation was sufficient for blinding subjects. 
The Shapiro-Wilk test for normality suggested that the data was normally distributed. In fact, for 
our main outcome (PPT), our results obtained a W score of 0.97 (p=0.18). 
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Changes in Pressure-Pain Threshold 
We analyzed whether stimulation condition was associated with an altered threshold for 
pain perception using a repeated-measures ANOVA. In this model, change in pain threshold (in 
units of pounds) was the dependent variable and the independent variables were condition (active 
tDCS, sham tDCS, DNIC, combined active tDCS and DNIC) and the random variable subject ID 
(allowing us to control for variability within subjects). The ANOVA showed a significant 
difference in outcomes between conditions (F(3,42)=8.12; p<0.001). 
We next performed post hoc analyses to compare the effects of the varying modulation 
conditions on pain thresholds. Two-tailed paired t-tests showed significant increases in pain 
threshold after active tDCS compared to sham conditions (p<0.05), after DNIC compared to 
sham conditions (p<0.005), and after combined active tDCS and DNIC compared to sham 
conditions (p<0.005) (See Figure 4). We did not observe a significant difference when 
comparing changes in pain threshold following active tDCS to changes in pain threshold 
following DNIC (p=0.35), suggesting that the pain modulation effects of these approaches as 
administered in our paradigm are comparable. Pain threshold increase following combined active 
tDCS and DNIC was significantly greater than following DNIC alone (p<0.01). While the pain 
threshold increase following combined active tDCS and DNIC was greater in magnitude than 
following active tDCS alone, this difference did not reach levels of significance (p=0.19). 
Of note, we found that subject responses to tDCS alone appeared to be associated with 
responses to combined tDCS and DNIC. Indeed calculation of Pearson’s correlation coefficient 
revealed that increases in pain threshold after active tDCS were positively and significantly 
correlated with increases after combined active tDCS and DNIC (r=0.54, p<0.05).  This may 
suggest that both interventions share similar predictors of response.  
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Changes in Sensory Threshold 
Von Frey hair test results were examined using repeated-measures ANOVA and two-
tailed paired t-tests. Change in thresholds for perceiving the sensory stimulus (Thresholdafter – 
Thresholdbefore) increased significantly following active tDCS compared to following sham tDCS 
(F(1,14)=5.88, p<0.05; 0.29±0.43 filament units increase following active tDCS vs. 0.00±0.37 
filament units increase following sham tDCS, p<0.05).  
 
Behavioral and Cognitive Assessment Results 
There were no significant differences in subject performance on the Beck depression 
inventory when administered prior to the active stimulation session compared to the sham 
stimulation session (1.20±2.14 vs. 1.27±2.49, p=0.86). Average VAS level of anxiety reported 
before stimulation (regardless of whether it was active or sham) was significantly higher than 
after stimulation (1.13±1.48 VAS units before vs. 0.83±1.14 VAS units after, p<0.05). Changes 
in reported anxiety were not significantly different following active stimulation compared to 
following sham stimulation. We did not observe significant differences in cognitive test 
performance after active tDCS compared to after sham tDCS.  
 
Brain Metabolite Concentration and Pain Modulation Response  
We performed exploratory post-hoc, correlational analyses to examine whether baseline 
concentrations of brain metabolites were associated with responses to the varying experimental 
conditions. We found that increase in pain threshold after active tDCS was positively correlated 
with total-NAA concentration in the anterior cingulate cortex (r=0.58, p<0.05), negatively 
correlated with Gln concentration and Gln/Cr in the thalamus (r=-0.60, p<0.05; r=-0.61, p<0.05, 
respectively), and positively correlated with mI concentration in the anterior cingulate cortex and   37 
occipital cortex (r=0.66, p<0.01; r=0.52, p<0.05, respectively). Pain threshold increase following 
sham tDCS was negatively correlated with Gln concentration in the anterior cingulate cortex, 
motor cortex, and occipital cortex (r=-0.53, p<0.05; r=-0.59, p<0.05; r=-0.54, p<0.05, 
respectively) and Gln/Cr in the motor cortex (r=-0.67, p<0.01). Pain thresholds measured during 
cold-water immersion (DNIC) prior to active stimulation were negatively associated with Glu 
and Glu/Cr in the occipital cortex (r=-0.54, p<0.0; r=-0.59, p<0.05, respectively). Pain thresholds 
after active tDCS administration were negatively correlated with Glu/Cr in the occipital cortex 
(r=-0.53, p<0.05) and positively correlated with mI in the anterior cingulate cortex (r=0.58, 
p<0.05). 
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Discussion 
Increase in Pain Thresholds 
In this investigation we aimed to compare exogenous (tDCS) and endogenous (DNIC) 
pain modulation approaches and determine whether their combination can result in synergistic 
effects on pain perception in healthy human subjects. We found that when administered alone 
both tDCS and the DNIC-induction paradigm significantly increased the thresholds at which 
subjects perceive pain compared to sham conditions. Interestingly, the pain threshold increases 
observed following tDCS alone and DNIC alone were not significantly different in magnitude. 
Furthermore, when combined, these modulatory approaches appeared to have additive effects in 
raising pain thresholds.  Activation of DNIC in conjunction with tDCS increased pain thresholds 
significantly greater than activation of DNIC alone. Thus, tDCS and DNIC appear to have 
additive, and possibly synergistic, effects. This observation is consistent with previous literature 
that found increased efficacies of pain and motor rehabilitation therapies when administered in 
combination with tDCS.
104-106 
From a theoretical point of view, there are a number of possible ways to explain the 
mechanistic underpinnings of our findings. It is plausible that the observed additive effect of 
these combined modulatory approaches results from influences on two distinct regions of neural 
activity mediating pain.  It is also possible that tDCS and DNIC in fact influence similar pain-
related regions, thus having additive effects by increasing the modulatory “dose” administered to 
these regions.  A third mechanism might involve one modulatory approach synergistically 
potentiating the other. For example, motor cortex stimulation with tDCS might facilitate activity 
in DNIC-related neural networks and therefore enhance their endogenous effects on pain, or vice 
versa.    39 
From a neurophysiological perspective, each of these theories is plausible and may help 
explain our observed findings. tDCS and DNIC appear to influence pain perception through 
different but partially overlapping neural pathways. Primary motor cortex stimulation with tDCS 
likely modulates pain through direct effects on ventral lateral and anterior thalamic nuclei (via 
cortico-thalamic pathways), which result in secondary modulatory effects on other pain-related 
regions such as the medial thalamus, anterior cingulate cortex, insula, and periaqueductal gray 
matter of the brainstem.
69,89-91,94 More specifically, lateral thalamic modulation induces inhibition 
of thalamic sensory neurons, cingulate modulation decreases emotional appraisal of pain, and 
periaqueductal gray modulation leads to descending inhibition toward the spinal cord.
91,92 Motor 
cortex stimulation may also cause endogenous opioid release and directly inhibit the 
somatosensory cortex.
91,93  
Pain modulation in DNIC is different from tDCS in that it begins with stimulation of the 
peripheral nervous system rather than CNS tissue, but it may ultimately influence some 
overlapping pain-related regions.  In DNIC, pain signals ascend through the spinal cord from the 
periphery and ultimately influence brainstem structures such as the subnucleus reticularis 
dorsalis of the caudal medulla which triggers descending inhibition of lamina I neurons in the 
spinal dorsal horn.
27,32-34,126 Similar to motor cortex stimulation, DNIC may also involve 
descending inhibition from periaqueductal gray matter, endogenous opioid release, and 
modulation of primary somatosensory cortical activity.
127 Thus, DNIC and motor cortex 
stimulation with tDCS may modulate pain through influences on distinct regions (e.g., lateral 
thalamus with tDCS; SRD with DNIC) or overlapping regions (e.g., periaqueductal gray matter 
with both).  Finally, it is possible that one of these approaches synergistically potentiates the 
other. For instance, neurons of the subnucleus reticularis dorsalis receive massive corticofugal   40 
projections and are modulated by the cingulate cortex, potentially explaining how cortical 
stimulation with tDCS could potentiate DNIC effects.
128,129 
As mentioned earlier, this experiment is consistent with a growing literature that suggests 
various pain and motor rehabilitation therapies are more effective when administered in 
conjunction with tDCS. For instance, combinations of transcutaneous electrical nerve stimulation 
and visual illusion therapy with tDCS have been found to treat chronic pain more 
effectively.
104,105 Similarly, in the setting of motor rehabilitation after stroke, outcomes are 
improved when tDCS is joined with constraint-induced movement therapy.
106 While this 
investigation involved healthy subjects, our results suggest that future work should examine 
whether the combination of tDCS and DNIC-related pain modulation might help in treating 
chronic pain patients. Fibromyalgia patients, for instance, have been found to have dysfunctional 
endogenous pain inhibition (DNIC)
37 and this deficiency has been associated with reduced 
activation of the rostral anterior cingulate cortex and associated brainstem regions, both of which 
play important roles in the endogenous pain regulatory system.
130 It is plausible that tDCS, which 
influences activity in the anterior cingulate cortex,
69 could enhance deficient endogenous pain 
modulatory activity in these patients through its effects on the ACC and brainstem regions 
involved in DNIC. 
 
Increase in Sensory Thresholds 
  A secondary aim of this investigation was to determine whether active tDCS alters the 
threshold for sensory perception as compared with sham tDCS. Using VFH monofilaments to 
measure sensory threshold, we found that active tDCS of the primary motor cortex does 
significantly increase the threshold for perceiving mechanical pressure sensation when compared 
to sham tDCS. This finding is consistent with previous literature.  For instance, Boggio and   41 
colleagues demonstrated in healthy subjects that anodal tDCS of the motor cortex increased 
thresholds for sensing a peripheral electrical stimulus by 6.5%.
131 They also found thresholds for 
perceiving this stimulus as painful to increase by 8.3%.  As expected, they did not observe 
significant alterations in sensory thresholds with stimulation of the dorsolateral prefrontal cortex, 
occipital cortex, or sham stimulation. Whereas Boggio and colleagues utilized peripheral 
electrical stimuli, we used mechanical stimuli (VFH). Therefore, our experiment contributes the 
finding that motor cortex stimulation using tDCS can increase thresholds for perceiving 
mechanical pressure sensation as well.  
  The effects of anodal tDCS on sensory thresholds are thought to be mediated through 
similar mechanisms as its effects on pain thresholds. That is, motor cortex stimulation likely 
modulates sensory and pain perception via corticothalamic modulation of epicritic (touch) and 
nociceptive neural activity in the ventral posterolateral and ventral posteromedial nuclei of the 
thalamus, respectively.
131 Alternatively, it is possible that direct stimulation of the nearby 
somatosensory cortex during administration of motor cortex stimulation may mediate the 
observed increases in sensory thresholds.
131,132  
  Of note, in designing our study, we chose not to examine the effects of DNIC on sensory 
threshold. Subjects are required to have their contralateral hand in painful, ice-cold water during 
induction of DNIC.  Von Frey hair sensory testing is relatively time-consuming to administer. 
For practical and ethical reasons, we therefore decided to examine only our primary outcome of 
pain threshold during DNIC-induction and not require subjects to undergo additional VFH 
testing. 
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Review of Adverse and Cognitive Effects 
 No significant adverse effects were reported in this study and the side effects that were 
reported, such as brief tingling sensation, were consistent with previous studies.
68,124 To monitor 
for subtle adverse effects of tDCS on cognitive functioning we administered several cognitive 
assessments. As expected, we did not observe significant differences in cognitive test 
performance after active tDCS compared to sham conditions. While some previous studies have 
observed improved performance on cognitive assessments following administration of tDCS, 
these improvements usually only take place after multiple stimulation sessions and involve 
stimulation of other cortical regions such as the prefrontal cortex and posterior temporo-parietal 
junction.
133-135 
 
Insights from Magnetic Resonance Spectroscopy 
Using the occipital cortex as our control, we explored whether baseline metabolite 
concentrations in the motor cortex, thalamus, and anterior cingulate cortex significantly correlate 
with subject responses to pain modulatory interventions. We observed that pain threshold 
increases following active tDCS were positively correlated with baseline total-NAA in the 
anterior cingulate cortex and negatively correlated with baseline glutamine levels in the 
thalamus. These findings are consistent with previous understandings of the role of these 
metabolites in brain function as well as related experimental findings.  
NAA has been viewed as a marker of neural density, viability, and overall function, with 
decreased levels often suggesting impaired neural functioning.
108-110 A 2002 study comparing 
brain metabolite concentrations in healthy subjects to those in chronic pain patients following 
spinal cord injury found that chronic pain patients had lower concentrations of NAA in the 
thalamus.
136 Low thalamic NAA levels have been observed as well in patients with chronic   43 
neuropathic pain,
112 trigeminal neuralgia,
113 and migraine.
114 Furthermore, chronic pain patients 
have been found to have decreased concentrations of NAA in the prefrontal cortex and anterior 
cingulate cortex.
137,138 More recently, researchers have demonstrated that chronic visceral pain 
improvement is associated with increases in NAA levels following TMS treatment.
117 Thus, 
decreased NAA in pain-related regions appears to be associated with chronic pain states and to 
increase with pain improvement. Our observation that higher NAA is associated with greater 
pain threshold increases after tDCS might be explained as follows: better baseline neural 
functioning is more conducive to tDCS having its neuromodulatory effects. As discussed in the 
limitations section below, however, we cannot firmly conclude any such causal relationship from 
the observed correlation alone. Our observation also raises the question of whether chronic pain 
patients (with low baseline NAA levels) might experience relatively diminished pain modulatory 
effects following tDCS compared to those seen in our healthy subjects (who likely have higher 
baseline NAA). Given the exploratory nature of these findings, it would be too early to answer 
this question firmly. 
Glutamine is a precursor to glutamate, which is a major excitatory neurotransmitter 
known to be involved in pain neurophysiology. Levels of glutamate and glutamine, which are 
often grouped together, can be influenced by non-invasive brain stimulation.
139 Pain relief in 
chronic pain patients has been linked to decreasing glutamate levels in the insular cortex.
115 A 
recent TMS study found that decreased baseline levels of glutamate were associated with greater 
chronic pain improvement following non-invasive brain stimulation.
117 Our findings are 
consistent with this previous literature and go beyond, demonstrating that lower levels of 
glutamine-glutamate at baseline are associated with greater pain neuromodulatory effects of 
tDCS, albeit in healthy subjects.    44 
Our combined observations from this exploratory analysis suggest that MRS assessment 
of brain metabolite levels may potentially be a useful tool for predicting response to pain 
modulatory interventions. We showed that, in healthy subjects, lower baseline concentrations of 
thalamic glutamine are associated with higher pain threshold increases following tDCS and that 
higher baseline concentrations of NAA in the anterior cingulate cortex are associated with higher 
pain threshold increases following tDCS.   
 
Limitations 
There are several limitations to this investigation that should be addressed. Though we 
did not observe a significant difference between the effects of tDCS and DNIC alone, it is 
important to highlight that manipulation of dosage could substantially alter pain responses.  
tDCS, for example, could potentially be administered with varying duration and current density, 
and DNIC could have been induced with varying durations of immersion and water 
temperatures.
140 It would therefore be incorrect to conclude from our study that tDCS and DNIC 
necessarily have similar magnitudes of effect under any conditions. As the mechanisms 
underlying these modulatory approaches continue be examined, the dosages of each should be 
adjusted to explore optimal combinations and parameters for increasing pain thresholds.  
Our study design called for the DNIC paradigm to be administered both before and after 
tDCS application. This sequence allowed us to test pain thresholds (1) at baseline, (2) during 
DNIC alone, (3) after active or sham tDCS, and (4) after active/sham tDCS during DNIC 
(combined condition). This design assumes that the initial DNIC-induction has no carry-over 
effects when assessing thresholds immediately following tDCS application (during #3 above). 
We believe this is a fair assumption. It is supported by the brief time length of the cold-water 
immersion (1-minute) and the fact that we had at least 15 minutes of cognitive assessments and   45 
20 minutes of tDCS stimulation before the post-tDCS pain threshold assessments took place. In 
contrast, when assessing combined tDCS and DNIC (#4 above) we assumed that there was a 
carry over effect from tDCS during DNIC administration, allowing us to consider this a 
combined tDCS and DNIC condition.  This assumption is supported by previous studies showing 
that brief sessions of tDCS (up to 13 minutes) can have effects lasting up to 90 minutes
65 and the 
fact that the DNIC pain threshold assessments were performed within minutes after tDCS 
application. 
We found that active tDCS combined with DNIC significantly increased pain thresholds 
more than DNIC alone, suggesting an additive or synergistic effect. While there also appeared to 
be a trend in which active tDCS combined with DNIC increased thresholds more than active 
tDCS alone, this did not reach the level of significance. It is unclear how this should be 
interpreted.  A strict interpretation would suggest that combined tDCS and DNIC provides 
significantly enhanced neuromodulatory effects on pain compared to DNIC alone, but not 
compared to tDCS alone. It seems possible that with a greater sample size and higher-powered 
study, we might find the observed trend to reach significance and see combined tDCS and DNIC 
increase thresholds significantly more than tDCS alone. At this point, however, that is 
speculative.  Importantly, we cannot conclude based on the data presented here whether the 
combined effects of tDCS and DNIC are additive or synergistic (i.e., equal to the sum of the 
effects of each administered alone [additive] vs. greater than the sum of the effects of each 
administered alone [synergistic]).  While they appear additive, higher powered studies would be 
necessary to confirm this. 
With regard to adverse effects, it reassuring that we did not observe any significant 
adverse effects. We also did not observe any instances of acute mood changes, trouble 
concentrating, and neck pain. One caveat, however, is that the adverse effects questionnaire was   46 
administered immediately following stimulation. In retrospect, it may have been beneficial to 
include a follow-up call to subjects the day after stimulation as well to ensure no adverse effects 
took place several hours after stimulation. While previous studies have not found this to occur, 
this would be a simple step to ensure no adverse effects are missed.
68,124  
As a point of clarification, I refer to DNIC as “endogenous” pain modulation and tDCS as 
“exogenous,” because DNIC is part of an endogenous regulatory system that naturally responds 
to modulate pain whereas tDCS requires an “exogenous” tool to modulate pain. To be clear, 
however, when the motor cortex is stimulated with anodal tDCS, the downstream effects likely 
do involve activation of endogenous pain regulatory processes. As discussed above, for instance, 
it is believed tDCS influences the periaqueductal gray matter, which triggers descending 
inhibitory signals down the spinal cord. Thus, even “exogenous” pain interventions like tDCS 
will ultimately involve many endogenous processes in modulating pain.
91,92 
It is important to emphasize that this study was conducted in healthy human subjects 
using acute, experimentally-induced pain and its conclusions can therefore not be generalized to 
chronic pain patients. It is very possible that our experimental paradigm would not produce the 
same results in chronic pain patients.  As discussed earlier, DNIC is found to be impaired in 
some chronic pain populations.
37,130 Our DNIC-induction paradigm might therefore demonstrate 
varying effects in these populations. Baseline brain metabolite concentrations also vary between 
healthy humans and chronic pain patients, with chronic pain patients having lower levels of 
metabolites such as NAA in certain brain regions.
136  Given these differing baseline 
neurophysiological states, chronic pain patients may react differently to tDCS than healthy 
humans. At the same time, this study provides valuable information about the effects of DNIC 
and tDCS in modulating pain under normal physiological conditions and, importantly, provides a 
point of comparison for future studies in chronic pain populations (discussed below).   47 
With respect to our MRS findings, it is important to mention that given our small sample 
size and post-hoc approach, our findings must be interpreted with caution. In these post hoc 
exploratory analyses, there was no power to correct for multiple comparisons, a limitation of 
which the reader should be aware due to the higher false positive rate. Several associations 
between metabolite concentrations and pain responses were observed to take place in both the 
occipital cortex and our regions of interest. Since the occipital cortex was our control region for 
the analysis, we deemed these associations insignificant. In contrast, the significant associations 
with NAA and glutamine discussed above were observed only in our regions of interest and not 
the control occipital region. While we deemed these significant, these associations must still be 
interpreted with caution, due to the post hoc nature of these analyses and lack of Bonferroni 
correction.  
Finally, it is necessary to highlight that these correlations between baseline metabolite 
levels and pain modulation responses do not imply causation. Even if we could confirm that 
various brain metabolite levels are strongly associated with response to pain modulatory 
interventions, these metabolites would not necessarily have to be in the mechanistic pathway 
mediating neuromodulatory response. For instance, a separate biological variable may both cause 
high levels of NAA and facilitate neuromodulatory response, allowing NAA to serve as a 
biomarker or predictor of response, while still not being on the mechanistic pathway mediating 
neuromodulatory response. 
 
Future Directions 
  The current study suggests many potential directions for future research. We should 
continue testing new technologies, techniques, and parameters as we attempt to identify even 
more effective pain modulatory approaches.  For example, the present paper explores the effects   48 
of anodal tDCS on pain thresholds. This follows from a vast literature demonstrating anodal 
stimulation to be efficacious in healthy and chronic pain populations.
94,96,105,141,142 Cathodal 
tDCS also appears to exert significant effects in modulating experimental pain.
143-145 Future 
studies should therefore explore the pain modulatory effects of cathodal tDCS and other 
stimulation techniques such as alternating current tDCS.
57  We should aim to maximize pain 
modulation by varying other tDCS parameters as well, such as electrode size, current intensity, 
duration, stimulation site, and number of stimulation sessions.
92 For instance, 4x1 ring high-
definition tDCS (HD-tDCS) is a promising new tool that uses an array of smaller electrodes to 
allow for greater focusing of current on stimulated regions.
146 We should explore stimulation of 
other cerebral cortical regions as well, such as the dorsolateral prefrontal cortex, since they may 
influence pain through different mechanisms.
147,148 Parameters for inducing DNIC can be 
modified as well by using different noxious stimuli (cold, electrical, heat, mechanical) for 
varying durations and number of repetitions. 
Eventually, the most effective techniques identified should be tested in clinical trials with 
chronic pain patients so their therapeutic value can be evaluated. The present study, after all, was 
performed in healthy human subjects and its results cannot be generalized to chronic pain 
patients, who may react very differently to pain modulation techniques. We should explore the 
possibility of enhancing existing pain therapies, whether pharmacologic or otherwise, through 
combinations with various neuromodulation techniques.
104-106 We might also attempt combining 
various neuromodulatory tools such as tDCS and TMS. As we plan for these clinical trials, we 
need to be cautious in choosing our inclusion and exclusion criteria. While this thesis often refers 
to chronic pain in general terms, chronic pain is in fact a highly heterogeneous condition and its 
pathophysiology can vary greatly between types.  Thus we need to take care to pick well-defined 
patient populations for trials and prevent ourselves from overgeneralizing results.   49 
We should also aim to identify and understand pain therapies that employ DNIC 
analgesic mechanisms. For instance, some have theorized that non-pharmacologic pain therapies 
such as acupuncture and transcutaneous electrical nerve stimulation may contribute to analgesia, 
in part, through activation of DNIC.
7,42-44 Endogenous pain modulation may also provide a 
mechanistic basis for placebo-induced analgesia.
41 A better understanding of the 
neurophysiology of DNIC and its roles in existing pain therapies may reveal new paradigms for 
pain treatment.  Furthermore, the manner in which attentional factors influence DNIC’s effect on 
pain when combined with tDCS and other therapies ought to be explored.
149 
Much remains to be understood regarding the neurophysiology underlying the effects of 
tDCS. As discussed above, tDCS exerts its effects by directly and indirectly modulating activity 
in a wide array of superficial and deep neural structures. Future research in healthy and patient 
populations should utilize brain imaging to help elucidate the mechanisms of tDCS’s effects in 
more detail. For instance, we might scan subjects using functional magnetic resonance imaging 
(fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), and 
electroencephalography (EEG) before, during, and following the administration of tDCS. This 
combination would provide high spatial resolution (MRS), data on neurochemical changes and 
glucose metabolism (PET, MRS), and information on system wide, oscillatory changes (EEG). 
Such imaging modalities applied to awake animal models might prove extremely valuable in 
further probing the neurophysiological effects of tDCS.  
The results from the exploratory MRS analyses in the present study suggest that baseline 
metabolite levels may be associated with response to neuromodulatory interventions. Future 
work should more rigorously test these associations both in healthy and patient populations. Our 
study design did not include a post-stimulation MRS session, because subjects only underwent a 
single short stimulation session. Follow-up investigations should involve multiple sessions as   50 
well as pre- and post-stimulation MRS scans to evaluate neurochemical changes involved in pain 
modulation.  
Furthermore, future research should explore the utility of MRS as a potential diagnostic 
and prognostic tool in the area of chronic pain. Harris and Clauw proposed that MRS might be 
used to develop “personalized” analgesic therapy for chronic pain patients.
111 This proposal 
developed from the observation that there are many types of chronic pain and no single 
medication that helps all patients. They proposed pre-treatment scanning of chronic pain patients 
with MRS to assess dysfunctional levels of brain metabolites such as glutamate and GABA, 
which could then be used to “personalize” treatment.  For instance, patients with elevated levels 
of glutamate (the excitatory neurotransmitter involved in pain) might be treated with a drug that 
targets glutamatergic neurotransmission, such as pregabalin. Similarly, those patients with low 
levels of GABA (the neurotransmitter that inhibits pain pathways) might receive GABA-ergic 
medications, such as beta-hydroxybutyrate. Patients with both findings, could be treated with 
dual therapy.
111 This exciting proposal could potentially lead to a paradigm shift in pain 
therapeutics, transitioning us away from the current trial-and-error standard and toward a more 
calculated, mechanistically focused approach. 
Finally, from a health policy perspective, there are important measures that can be taken 
to advance pain research generally. As mentioned in the opening of this thesis, chronic pain 
constitutes a major burden of disease in society, with 1.5 billion people worldwide estimated to 
suffer from various forms.
1  While more individuals in the US are affected by chronic pain than 
cancer, diabetes, and heart disease combined, pain research is currently granted less than 1% of 
the budget of the National Institutes of Health (NIH).
1,2 Over the last half-century, fewer than 10 
pharmaceutical drugs with new mechanisms of action have been introduced. Only one 
medication now being used clinically has been designed based on targeted mechanisms of action   51 
(i.e., triptans for migraine treatment).
2 Pain represents a major public health challenge that 
demands prompt attention. The federal government and NIH ought to commit more funding to 
support research that aims to better understand the neural mechanisms underlying physiologic 
and pathologic pain as well as to develop novel pharmacologic, neuromodulatory, and other 
treatments for acute and chronic pain. More effective integration of pain research at the National 
Institutes of Health and in academic centers nationally would help to further these goals.
2 
 
Summary and Conclusions 
This thesis explored whether combining exogenous and endogenous pain modulation 
approaches (anodal tDCS of M1 and a DNIC-induction paradigm, respectively), synergistically 
increases the threshold at which pain is perceived. We conducted a double-blinded, randomized, 
placebo-controlled trial with a crossover design in 15 healthy human subjects. We found that, 
when administered alone, both tDCS and DNIC significantly increased the thresholds at which 
subjects perceive pain. When combined, these modulatory approaches appeared to have additive 
effects. tDCS also significantly increased the threshold for perceiving sensation when compared 
to sham conditions. Finally, baseline concentrations of brain metabolites were significantly 
associated with the effects of tDCS on pain thresholds. Increases in pain threshold after tDCS 
were positively correlated with baseline levels of NAA in the anterior cingulate cortex and 
negatively correlated with baseline levels of glutamine in the thalamus. Future research should 
explore whether existing pain therapies may be improved with noninvasive brain stimulation and 
activation of endogenous pain regulatory systems such as DNIC. We should work to enhance 
pain modulation using alternative parameters for tDCS and DNIC-induction and to understand 
the neurophysiology underlying their effects. Finally, we ought to examine whether brain 
metabolite concentrations can be utilized to predict clinical response to therapeutic interventions.      52 
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Table 1. Varying Parameters of tDCS 
Parameter  Standard Range  Effect 
Electrode Size  20 cm
2 – 35 cm
2 
Smaller electrode size results in greater final cortical 
current density, but also greater shunting to the scalp. 
Unipolar stimulation can be achieved through a small 
electrode by enlarging the area of the other electrode. 
 
Current Intensity  1.0 mA – 2.0 mA 
A current intensity of 0.6 mA is necessary to observe 
after-effects. Larger current intensity results in greater 
amplitude of effect (as measured by MEPs) and longer-
lasting effects. 
 
Current Density on 
Scalp Surface   24 µA/cm
2 – 29 µA/cm
2 
Larger current densities result in stronger effects of 
tDCS. Lower current densities (less than 24 µA/cm
2) for 
a few minutes do not induce any significant effects. 
(This is the ratio of current intensity and electrode size). 
 
Stimulation Duration  5 min – 30 min 
Longer duration results in longer-lasting effects. 
Whereas 5 to 7 minutes of tDCS results in after-effects 
lasting for no longer than 5 minutes, tDCS from 9 to 13 
minutes results in after-effects lasting from 30 to 90 
minutes, respectively. 
 
Stimulation Polarity  Anodal or Cathodal (applied 
to cortical region of interest) 
Effect depends strictly on the orientation of axons and 
dendrites in the induced electrical field. Generally, 
anodal tDCS increases the excitability of the underlying 
cortex by depolarizing neuronal membranes to 
subthreshold levels, while cathodal tDCS applied over 
the same area decreases it by hyperpolarizing neuronal 
membranes. 
 
Stimulation Site 
M1, V1, Somatosensory 
Cortex, Dorsolateral 
Prefrontal Cortex  
Site-specific and differential effects on a gamut of 
cognitive, behavioral, psychosomatic, and 
electrophysiological tests. While the polarizing effects 
of tDCS are generally confined to the areas under the 
electrodes, the functional effects appear to perpetuate 
beyond the immediate site of stimulation. Anodal tDCS 
of the premotor cortex, for instance, increases 
excitability of the ipsilateral motor cortex and inhibition 
of contralateral motor areas. 
 
Note: (Table excerpted with permission from Reidler et al. (2011)
150) 
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Table 2. Side effects of tDCS Administration 
 
  Active tDCS  Sham tDCS 
Tingling  11 (73)  10 (67) 
Skin Redness  7 (47)  8 (53) 
Sleepiness  5 (33)  6 (40) 
Itching  2 (13)  1 (7) 
Scalp Pain 
Scalp Burning 
Headache 
Pins and Needles 
Neck Pain 
Trouble Concentrating 
Acute Mood Change 
1 (7) 
1 (7) 
1 (7) 
1 (7) 
0 (0) 
0 (0) 
0 (0) 
2 (13) 
0 (0) 
1 (7) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Note: Number of subjects and percentage (in parentheses) reporting the side effect. (Table 
excerpted with permission from Reidler et al. (2012).
151) 
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Figure 1. Transcranial Magnetic Stimulation. A copper wire coil encased in plastic is placed 
on the subject’s scalp overlying the cortical region to be stimulated. As current is sent through 
the coil, a 2 Tesla magnetic field is generated in a perpendicular plane to the coil. This rapidly 
generated magnetic field penetrates the subject’s scalp and skull, inducing electrical current in 
the underlying cortical regions strong enough to depolarize cellular membranes and induce 
neuronal activity. (Figure excerpted with permission from Reidler et al. (2011)
150). 
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Figure 2. Transcranial Direct Current Stimulation. Two rubber electrodes are placed in 
saline-soaked sponges and then applied to the scalp. The electrodes are attached by wire to a 
battery-powered direct current generator. The tDCS operator sets the device’s internal resistance 
with a dial to reach a target current ranging from 0.5 mA to 2.0 mA. Current travels through the 
scalp and skull to the underlying cortex, inducing real-time neurophysiological effects. (Figure 
excerpted with permission from Reidler et al. (2011).
150 Redacted additional image of 
transcranial direct current stimulator excerpted from neuroConn.
152) 
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Figure 3. Experimental Design for Evaluating the Effects of tDCS and DNIC on Pain 
Thresholds.  The study design involved three visits. During Visit 1, subjects underwent 
magnetic resonance spectroscopy (MRS) to measure baseline metabolite concentrations in pain-
related regions of interest.  During Visit 2, subjects were randomized to receive active or sham 
anodal tDCS. This was preceded and followed by a series of assessments, which included the 
Visual Analog Scales (VAS) for anxiety, Von Frey Hair sensory threshold test, Pressure-Pain 
Threshold (PPT) measurements performed using an algometer on the right thenar region, PPT 
following the first 30 seconds of left hand cold-water immersion (DNIC paradigm), and 
cognitive assessments. During Visit 3, subjects underwent identical procedures as in Visit 2, with 
the only change being the active vs. sham stimulation conditions. This design allowed us to 
evaluate the effects of active tDCS, sham tDCS, DNIC, and combined conditions in all subjects 
(cross-over design). (Figure excerpted with permission from Reidler et al. (2012).
151) 
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Figure 4. Motor Cortex Stimulation and DNIC Increase Pain Thresholds. We compared 
subjects’ pain thresholds at baseline to their thresholds following administration of sham tDCS, 
active tDCS, DNIC, and combined active tDCS and DNIC. When compared to sham conditions, 
significant increases in pain thresholds were observed following active tDCS, DNIC, and 
combined conditions. Change in pain thresholds after active tDCS alone was not significantly 
different from change observed after DNIC alone. Combined active tDCS and DNIC increased 
pain thresholds more than either method alone, and this reached significant levels when 
compared to DNIC conditions. *, p < 0.05; **, p < 0.01; ***, p < 0.005 (paired t-test, 2-tailed). 
(Figure excerpted with permission from Reidler et al. (2012).
151) 
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Appendix B. Visual Analog Scale for Anxiety 
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Appendix C. Trail Making Tests 
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Appendix D. tDCS Side Effects Questionnaire 
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Appendix E. tDCS Blinding Questionnaire 
 
 
 
 
 